X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FULFORD INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FULFORD INDIA NOVARTIS/
FULFORD INDIA
 
P/E (TTM) x 447.0 398.8 112.1% View Chart
P/BV x 25.9 6.2 417.1% View Chart
Dividend Yield % 1.8 0.1 2,082.7%  

Financials

 NOVARTIS   FULFORD INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
FULFORD INDIA
Mar-14
NOVARTIS/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs758942 80.5%   
Low Rs579450 128.7%   
Sales per share (Unadj.) Rs228.4691.4 33.0%  
Earnings per share (Unadj.) Rs31.711.5 276.9%  
Cash flow per share (Unadj.) Rs32.815.4 213.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.3 520.6%  
Book value per share (Unadj.) Rs297.1380.0 78.2%  
Shares outstanding (eoy) m24.693.90 633.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.91.0 290.8%   
Avg P/E ratio x21.160.7 34.7%  
P/CF ratio (eoy) x20.445.3 45.0%  
Price / Book Value ratio x2.21.8 122.8%  
Dividend payout %31.517.4 180.6%   
Avg Mkt Cap Rs m16,5052,714 608.1%   
No. of employees `0000.70.4 150.5%   
Total wages/salary Rs m1,445505 286.2%   
Avg. sales/employee Rs Th8,441.36,073.0 139.0%   
Avg. wages/employee Rs Th2,163.61,137.4 190.2%   
Avg. net profit/employee Rs Th1,173.1100.7 1,165.2%   
INCOME DATA
Net Sales Rs m5,6392,696 209.1%  
Other income Rs m1,718125 1,370.3%   
Total revenues Rs m7,3572,822 260.7%   
Gross profit Rs m-63-46 134.7%  
Depreciation Rs m2515 166.4%   
Interest Rs m5510 582.1%   
Profit before tax Rs m1,57554 2,900.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m79210 8,245.8%   
Profit after tax Rs m78445 1,753.0%  
Gross profit margin %-1.1-1.7 64.4%  
Effective tax rate %50.317.7 284.2%   
Net profit margin %13.91.7 838.3%  
BALANCE SHEET DATA
Current assets Rs m9,5221,738 547.7%   
Current liabilities Rs m3,296545 605.1%   
Net working cap to sales %110.444.3 249.4%  
Current ratio x2.93.2 90.5%  
Inventory Days Days3748 75.5%  
Debtors Days Days284 660.3%  
Net fixed assets Rs m4612 386.6%   
Share capital Rs m12339 316.4%   
"Free" reserves Rs m7,2131,443 499.9%   
Net worth Rs m7,3361,482 495.0%   
Long term debt Rs m00-   
Total assets Rs m11,1052,077 534.8%  
Interest coverage x29.56.7 439.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.3 39.1%   
Return on assets %7.62.6 289.4%  
Return on equity %10.73.0 354.1%  
Return on capital %22.24.3 516.3%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m6117 352.3%   
Fx outflow Rs m3,630673 539.3%   
Net fx Rs m-3,570-656 544.2%   
CASH FLOW
From Operations Rs m1,61090 1,788.8%  
From Investments Rs m687105 656.8%  
From Financial Activity Rs m-2,677-14 18,982.3%  
Net Cashflow Rs m-380181 -210.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 3.8 52.6%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 21.2 101.4%  
Shareholders   41,647 4,783 870.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   VENUS REMEDIES  ORCHID PHARMA LTD  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 23, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PLETHICO PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS